Search research articles
Contact Us
Filters
Showing results (11-20 of 72) with videos related to
Page
of 8
Sort By:
Expert Review of Hematology
|
June 10, 2026
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis
Krina Patel, Ken Hasegawa, Surbhi Sidana, et al.
Cancers
|
December 23, 2023
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review
Doris K Hansen, Yi-Hsuan Liu, Sandip Ranjan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 31, 2025
Patient and caregiver perspectives on treatment decision-making for stem cell transplantation in multiple myeloma
Doris K Hansen, Todd Bixby, Karen Fixler, et al.
Blood Advances
|
December 27, 2024
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
Mahmoud R Gaballa, Omar Castaneda Puglianini, Adam Cohen, et al.
Frontiers in Immunology
|
September 5, 2024
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
Doris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.
Cancer Medicine
|
November 1, 2024
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma
Doris K Hansen, Santosh Gautam, Marie-Hélène Lafeuille, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
February 24, 2026
Comparative cost per responder analysis of Ciltacabtagene autoleucel and real-world standard of Care therapy in patients with lenalidomide-refractory multiple myeloma
Doris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.
Haematologica
|
February 5, 2026
Second primary malignancy in multiple myeloma: does a prior malignancy matter?
Alissa Visram, Hsien Seow, Rajeshkar Chakraborty, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 2, 2025
Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
Tobias Tix, Mohammad Alhomoud, Roni Shouval, et al.
Blood Cancer Journal
|
August 1, 2025
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
Mobina Golmohammadi, Shahzad Raza, Maram Albayyadhi, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 72) with videos related to
Sort By:
Page
of 8
Expert Review of Hematology
|
June 10, 2026
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis
Krina Patel, Ken Hasegawa, Surbhi Sidana, et al.
Cancers
|
December 23, 2023
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review
Doris K Hansen, Yi-Hsuan Liu, Sandip Ranjan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 31, 2025
Patient and caregiver perspectives on treatment decision-making for stem cell transplantation in multiple myeloma
Doris K Hansen, Todd Bixby, Karen Fixler, et al.
Blood Advances
|
December 27, 2024
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
Mahmoud R Gaballa, Omar Castaneda Puglianini, Adam Cohen, et al.
Frontiers in Immunology
|
September 5, 2024
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
Doris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.
Cancer Medicine
|
November 1, 2024
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma
Doris K Hansen, Santosh Gautam, Marie-Hélène Lafeuille, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
February 24, 2026
Comparative cost per responder analysis of Ciltacabtagene autoleucel and real-world standard of Care therapy in patients with lenalidomide-refractory multiple myeloma
Doris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.
Haematologica
|
February 5, 2026
Second primary malignancy in multiple myeloma: does a prior malignancy matter?
Alissa Visram, Hsien Seow, Rajeshkar Chakraborty, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 2, 2025
Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
Tobias Tix, Mohammad Alhomoud, Roni Shouval, et al.
Blood Cancer Journal
|
August 1, 2025
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
Mobina Golmohammadi, Shahzad Raza, Maram Albayyadhi, et al.
Page
of 8